Antianginal Efficacy of the Combination of Trimetazidine-Propranolol Compared with Isosorbide Dinitrate-Propranolol in Patients with Stable Angina
Tóm tắt
Trimetazidine is a new anti-ischaemic drug that exerts cytoprotective effects without modifying coronary blood flow or systemic haemodynamics. We tested the antianginal efficacy of trimetazidine in combination with propranolol, using a double-blind isosorbide dinitrate-controlled design. Male patients (n = 53) with stable, effort-induced angina not sufficiently controlled with propranolol 40rng 3 times daily received at random either trimetazidine 20mg 3 times daily (n = 27) or isosorbide dinitrate 10mg 3 times daily (n = 26) for 2 months. From day 0 to day 60, in both groups, there was a decrease in the average number of anginal attacks per week (p < 0.01) and in the weekly consumption of nitroglycerin (p < 0.01), the latter being more decreased in the trimetazidine group (p < 0.05). On exercise testing, both exercise duration and time to 1 mm ST depression were improved in the trimetazidine group at day 60 compared with day 0 values (p < 0.001), while no significant changes were observed in the isosorbide dinitrate group. The total workload increased significantly more in the trimetazidine group than in the isosorbide dinitrate group for patients performing the exercise test on a bicycle (n = 31, p < 0.001), but not on a treadmill (n = 22, p = not significant). We concluded that in patients with stable induced angina not sufficiently controlled with propranolol, a better antianginal efficacy was observed with the addition of trimetazidine than with the addition of isosorbide dinitrate, and this confirmed the clinical interest in the new anti-ischaemic drug.
Tài liệu tham khảo
Boddeke E, Hugtenburg J, Jap W, et al. New anti-ischaemic drugs: cytoprotective action with no primary haemodynamic effects. TIPS 1989; 10: 397–400
Detry JM. Clinical features of an anti-anginal drug in angina pectoris. Eur Heart J 1993; 14 Suppl. G: 18–24
Kober G, Buck T, Sievert H, et al. Myocardial cytoprotection during percutaneous transluminal coronary angioplasty: effect of trimetazidine. Eur Heart J 1992; 13: 1109–15
Fabiani JN, Ponzio O, Emerit I, et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg 1992; 33: 486–91
Brottier L, Barat JL, Combe L, et al. Therapeutic value of a cardioprotective agent in patients with severe cardiomyopathy. Eur Heart J 1990; 11: 207–12
De Leiris J, Boucher F. Rationale for trimetazidine administration in myocardial ischaemia — reperfusion syndrome. Eur Heart J 1993; 14 Suppl. G: 34–40
Sellier P. Effets de la trimétazidine sur les paramètres ergométriques dans 1’angor d’effort. Etude multicentrique contrôlée à double insu contre placebo. Arch Mal Coeur 1986; 79(9): 1331–6
Prasad R, Singh HK. The efficacy of trimetazidine in stable effort angina. A double-blind placebo controlled study. Indian Med J 1989; 83(3): 54–8
Dalla-Volta S, Maraglino G, Delia-Valentina B, et al. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, cross-over study. Cardiovasc Drug Ther 1990; 4(4): 853–60
Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina — comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994; 37(3): 279–88
Frischman WH. β-Adrenoreceptor antagonists: new drugs and new indications. New Engl J Med 1981; 305: 500–6
Bernard R, Eliasch H, Gonin A, et al. Nomenclature and criteria 2 for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force for standardization of clinical nomenclature. Circulation 1979; 59: 607–9
Campeau L. Grading of angina pectoris. Circulation 1976; 54: 522
Chierchia S, Muisean L, Davies A, et al. Role of the sympathetic nervous system in the pathogenesis of chronic stable angina. Circulation 1990; 82 Suppl. II: II71–II81
Svendsen JH, Amtorp A. Mononitrates in combination with beta-blocker therapy in the treament of severe angina pectoris. Drugs 1987; 33 Suppl. 4: 122–4
Michaelides AP, Vyssoulis GP, Bonoris PE, et al. Beneficial effects of trimetazidine in man with stabla angina under beta-blocker treatments. Curr Ther Res 1989; 46(3): 565–76
Delaye J. Le phénomène de l’échappement dans la pratique thérapeutique de l’angine de poitrine. Presse Med 1988; 17: 996–9
Weidemann H, Schuon J, Schober B, et al. Hemodynamic measurements and exercise testing to assess the development of tolerance against slow release isosorbide dinitrate. Z Kardiol 1983; 72: 229–32
Pornin M, Harpey C, Allai J, et al. Lack of effects of trimetazidine on systemic hemodynamics in patients with coronary artery disease: a placebo controlled study. Clin Trials Meta-Anal 1994; 29: 49–56
Boucher F, Hearse D, Opie L. Effects of trimetazidine on ischemic contracture in isolated perfused rat hearts. J Cardiovasc Pharmacol 1994; 24: 45–9
Belcher P, Drake-Holland AJ, Hynd JW, et al. Trimetazidine reduces myocardial infarct size, relative to area at risk, after temporary coronary artery occlusion in the rabbit. Br J Pharmacol 1992; 107: 265
Chierchia SL, Fragasso G, Metabolic management of ischaemic heart disease. Eur Heart J 1993; 14 Suppl. G: 2–5
Hugtenburg JG, Jap TSW, Mably JJ, et al. Cardioprotective effect of trimetazidine and nifedipine in guinea-pig hearts subjected to ischemia. Arch Int Pharmacodyn Ther 1989; 300: 186–208
Lavanchy N, Martin J, Rossi A. Antiischemic effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987; 286: 97–110
Aussedat J, Ray A, Kay L, et al. Improvement of long-term preservation of isolated arrested rat heart: beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol 1993; 21(6): 128–35
Williams FM, Tanda K, Williams TJ. Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993; 22: 828–33
Maupoil V, Rochette L, Tabard A, et al. Evolution of free radical formation during low-flow ischemia and reperfusion in isolated rat heart. Cardiovasc Drugs Ther 1990; 4: 791–6
Fantini E, Demaison L, Sentex E, et al. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Moll Cell Cardiol 1994; 26: 949–58
Lagadic-Gossmann D, Le Prigent K, Feuvray D. Effects of trimetazidine on pHi regulation in the rat isolated ventricular myocyte. Br J Pharmacol 1996; 117: 831–8
Gobel FL, Nordstrom LA, Nelson RR, et al. The rate pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris. Circulation 1978; 57: 549–54
Myers J, Proelicher VF. Optimizing the exercise test for pharmacological investigations. Circulation 1990; 82: 1839–46
Northride DB, Grant S, Ford I, et al. Novel exercise protocol suitable for use on a treadmill or a bicycle ergometer. Br Heart J 1990; 64: 331–6